| Kang, Won Ki |
NCT04584242: Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes |
|
|
| Recruiting | 4 | 40 | RoW | gluconon tab 15mg, suganon tab 5mg | Yonsei University | Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes | 05/22 | 05/22 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Choi, Seung Ho |
NCT06543758: Effectiveness and Safety of At-home Gait Rehabilitation Using Wearable Exoskeletal Robot |
|
|
| Not yet recruiting | 4 | 16 | RoW | Wearable exoskeletal robot | Yonsei University | Stroke, Gait, Spastic, Gait, Hemiplegic | 07/25 | 07/26 | | |
NCT05526703: Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy |
|
|
| Recruiting | 3 | 108 | RoW | D064, D701, placebo of D012, D064, D701 are consisted of antihypertensive agent., D012, placebo of D064, placebo of D701, D012 is consisted of antihypertensive agent. | Chong Kun Dang Pharmaceutical | Essential Hypertension | 10/23 | 10/23 | | |
NCT04797923: A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination |
|
|
| Recruiting | 2 | 43 | RoW | 1. Treatment: IP chemotherapy + Systemic chemotherapy, 2. Response evaluation after 4 cycles of IP + systemic chemotherapy | Gangnam Severance Hospital | Advanced Gastric Cancer, Peritoneal Carcinomatosis | 06/21 | 12/21 | | |
NCT06722768: Identifying Gait Changes From a CSF Tap Test Using a Smart Insole in iNPH |
|
|
| Recruiting | N/A | 50 | RoW | | Yonsei University | Normal Pressure Hydrocephalus | 02/25 | 02/25 | | |
NCT06442982: Analyzing Gait Pattern Using Insole-type Gait Analyzer in Patient With Gait Disturbance |
|
|
| Recruiting | N/A | 600 | RoW | insole-type gait analyzer | Yonsei University | Gait Disorders, Neurologic | 01/25 | 05/25 | | |
| Recruiting | N/A | 140 | RoW | Renal Denervation | Kalos Medical | Hypertension, Vascular Diseases, Cardiovascular Diseases | 07/23 | 04/24 | | |
NCT06410755: Home-based Gait Rehabilitation Service Using Instrumented Insole |
|
|
| Recruiting | N/A | 30 | RoW | Monitoring system using a insole-type gait analyzer | Yonsei University, Korea Health Industry Development Institute | Gait Disorders, Neurologic | 04/24 | 12/25 | | |
| Kwon, Hyuk-Sang |
NCT06712615: Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes |
|
|
| Recruiting | 2 | 144 | RoW | PG-102, Placebo | ProGen. Co., Ltd. | Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus | 03/25 | 06/25 | | |
NCT05754775: Remission of Type 2 Diabetes Via Calorie Restriction |
|
|
| Enrolling by invitation | N/A | 40 | RoW | Calorie restriction via total food replacement | Yeouido St. Mary's Hospital | Type 2 Diabetes, Obesity, Morbid | 08/24 | 02/26 | | |
| Kim, Jin Seok |
KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy |
|
|
| Active, not recruiting | 3 | 358 | RoW | Chemotherapy | Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology, Pharmbio Korea Inc., Samjin Pharmaceutical Co., Ltd., Boryung Pharmaceutical Co., Ltd, JW Pharmaceutical | Rectal Cancer | 07/23 | 06/26 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 496 | RoW | Neu2000KWL group, Placebo group | GNT Pharma | Ischemic Stroke | 06/24 | 01/25 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
CLAUDIA, NCT05534087: Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) |
|
|
| Recruiting | 3 | 236 | RoW | mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy | Seoul National University Hospital | Colon Cancer | 09/28 | 09/30 | | |
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL |
|
|
| Recruiting | 3 | 504 | Europe, US, RoW | Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone | Acrotech Biopharma Inc. | Peripheral T Cell Lymphoma | 07/30 | 11/30 | | |
NCT03597087: The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study |
|
|
| Not yet recruiting | 2 | 289 | RoW | Anesthesia before transurethral resection of the bladder tumor, Anesthesia | Seoul National University Hospital | Bladder Cancer | 07/21 | 12/22 | | |
NaliCap, NCT04371224: (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 200 | RoW | Irinotecan Liposomal Injection [Onivyde], nal-IRI, Capecitabine, xeloda, 5-fluorouracil, 5FU, Leucovorin, LV | Seoul National University Hospital | Pancreatic Cancer | 12/24 | 12/25 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
| Recruiting | 1/2 | 387 | Europe, Japan, US, RoW | Linvoseltamab, REGN5458 | Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc. | Multiple Myeloma | 05/32 | 06/32 | | |
|
|
|
|
|
NCT04492033: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients |
|
|
| Terminated | 1/2 | 41 | RoW | CTX-009 (ABL001), Paclitaxel, Irinotecan | Handok Inc., Compass Therapeutics, ABL Bio, Inc. | P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer | 01/24 | 01/25 | | |
| Recruiting | 1/2 | 148 | Europe, US, RoW | AFM24, Atezolizumab 840 MG in 14 ML Injection | Affimed GmbH, Affimed GmbH | Advanced Solid Tumor | 02/25 | 11/25 | | |
ACCENT, NCT05355298: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 62 | RoW | AMP945 ascending doses, AMP945 RP2D | Amplia Therapeutics Limited | Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma | 05/25 | 05/25 | | |
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 148 | RoW | HM95573, cobimetinib, HM95573, cetuximab | Hanmi Pharmaceutical Company Limited | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 09/24 | 12/24 | | |
| Recruiting | 1 | 144 | Europe, Canada, US, RoW | Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone | GlaxoSmithKline | Multiple Myeloma | 11/24 | 06/25 | | |
|
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function |
|
|
| Recruiting | 1 | 28 | Europe, US, RoW | Belantamab mafodotin | GlaxoSmithKline | Multiple Myeloma | 11/25 | 11/25 | | |
NCT04722705: Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention |
|
|
| Recruiting | N/A | 30 | RoW | fractional Er:YAG laser, Matrixell, Medro corp., Seoul, Korea, Intense pulse light, IPL (Ellipse Flex, DDD, Hoersholm, Denmark) | Hallym University Kangnam Sacred Heart Hospital | Intense Pulsed Light, Erbium-yttrium Aluminum Garnet Laser, Scar Prevention | 11/21 | 11/21 | | |
| Recruiting | N/A | 100 | RoW | Two-in-one stent | Ajou University School of Medicine | Extrahepatic Bile Duct Cancer, Pancreatic Cancer, Lymph Node Metastases, Gallbladder Cancer | 12/21 | 12/21 | | |
NCT04835467: First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI |
|
|
| Completed | N/A | 40 | RoW | Dual-modal OCT-FLIm | Korea University Guro Hospital | Atherosclerosis Coronary Artery With Angina Pectoris, Atheroscleroses, Coronary, Atherosclerotic Plaque, Thin-cap fIbroatheroma, Atherosclerosis | 08/22 | 10/23 | | |
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma |
|
|
| Completed | N/A | 203 | RoW | | Boryung Pharmaceutical Co., Ltd | Multiple Myeloma | 01/23 | 01/23 | | |
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma |
|
|
| Approved for marketing | N/A | | Europe, Canada, US, RoW | Olaratumab, LY3012207 | Eli Lilly and Company | Soft Tissue Sarcoma | | | | |
NCT04853511: Comprehensive Assessment of Interconnection Between Brain Emotional Activity and Coronary Plaque Instability |
|
|
| Recruiting | N/A | 200 | RoW | OCT-FLIM (optical coherence tomography-fluorescence life time), 18F-FDG-PET/CT (positron emission tomography-computed tomography) | Korea University Guro Hospital | Atherosclerosis, Coronary, Emotional Stress, Inflammation, Hematopoiesis, Atherosclerosis Coronary Artery With Angina Pectoris, Atheroma; Heart, Atherosclerosis, Acute Coronary Syndrome | 12/23 | 12/24 | | |
| Lee, Han Chu |
NCT04554758: Comparative Analysis Between Sleeve Gastrectomy and Roux-en Y Gastric Bypass in Bariatric Operation |
|
|
| Recruiting | N/A | 400 | RoW | Sleeve gastrectomy, Roux-en-Y gastric bypass | Inha University Hospital, Korean Center for Disease Control and Prevention | Obesity, Morbid, Overnutrition, Nutrition Disorders, Overweight and Obesity, Body Weight Changes | 08/22 | 08/23 | | |
| Recruiting | N/A | 140 | RoW | Renal Denervation | Kalos Medical | Hypertension, Vascular Diseases, Cardiovascular Diseases | 07/23 | 04/24 | | |
NCT05737017: The Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet) |
|
|
| Recruiting | N/A | 400 | RoW | ClearCoajet | Seoul St. Mary's Hospital | Colonic Polyps | 10/23 | 12/23 | | |
NCT05309642: Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study |
|
|
| Completed | N/A | 72 | RoW | Intermittent calorie restriction, Standard of care | Ewha Womans University Mokdong Hospital | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 12/23 | 12/23 | | |
| Active, not recruiting | N/A | 994 | RoW | Staged in-hospital or Immediate complete revascularization | Chonnam National University Hospital | Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis | 02/25 | 12/29 | | |
NCT04740346: Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP) |
|
|
| Recruiting | N/A | 886 | RoW | Computed tomography, Chest X-ray, and blood test | National Cancer Center, Korea, Korea Health Industry Development Institute | Gastric Cancer, Recurrence, Quality of Life | 06/26 | 06/26 | | |
| Terminated | N/A | 89 | RoW | SurePath™ | Seoul National University Hospital | Submucosal Tumor of Gastrointestinal Tract | 01/22 | 01/23 | | |
NCT05183256: Cohort of Inflammatory Bowel Disease Patient in Yeouido St. Mary's Hospital |
|
|
| Completed | N/A | 28 | RoW | | Yeouido St. Mary's Hospital | Inflammatory Bowel Diseases | 06/23 | 07/23 | | |
| Jeon, Young Kwan |
Capella, NCT05493800: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT |
|
|
| Active, not recruiting | 2 | 60 | RoW | MIT-001, normal saline, placebo | MitoImmune Therapeutics | Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer | 06/24 | 12/24 | | |
| Recruiting | 2 | 33 | RoW | R2P -> RP | NOBO Medicine | Primary CNS Lymphoma (PCNSL) | 06/26 | 12/27 | | |
| Kim, Youngkook |
NCT05539690: Effect of Balance Training on White Matter Tracts in Healthy Elderly Population |
|
|
| Recruiting | N/A | 40 | RoW | Balance training | The Catholic University of Korea | Postural Balance, Neuronal Plasticity, Elderly Population | 08/23 | 02/24 | | |
| Kim, Ilsoo |
NCT05183256: Cohort of Inflammatory Bowel Disease Patient in Yeouido St. Mary's Hospital |
|
|
| Completed | N/A | 28 | RoW | | Yeouido St. Mary's Hospital | Inflammatory Bowel Diseases | 06/23 | 07/23 | | |
| Hong, Kyeongshin |
NCT05183256: Cohort of Inflammatory Bowel Disease Patient in Yeouido St. Mary's Hospital |
|
|
| Completed | N/A | 28 | RoW | | Yeouido St. Mary's Hospital | Inflammatory Bowel Diseases | 06/23 | 07/23 | | |
